Interestingly, ZNRF3 deep deletions are also observed in primary and metastatic prostate cancer (≤2%) (Tables S1–S4), potentially promoting Wnt signaling via the stabilization of FZD receptors and Wnt co-receptors at the plasma membrane. This evidence concerns the gene ZNRF3 and metastatic prostate carcinoma.